Direct and selective pharmacological disruption of the YAP ...

IAG933, a novel YAP-TEAD interaction disruptor, shows promise in preclinical trials for treating Hippo pathway-altered cancers, including mesothelioma, lung, pancreatic, and colorectal cancers. It induces cell death, reduces tumor growth, and enhances efficacy when combined with other therapies. Clinical trials are underway.